Top Page
SSY Group
(OTC:2005)
SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)
SSY Group Business Overview & Revenue Model
SSY Group Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.77B | 6.46B | 6.43B | 5.36B | 4.26B | Gross Profit |
| 2.91B | 3.62B | 3.44B | 3.04B | 2.58B | EBIT |
| 1.34B | 1.64B | 1.36B | 903.79M | 687.16M | EBITDA |
| 1.74B | 2.11B | 1.86B | 1.40B | 1.09B | Net Income Common Stockholders |
| 1.06B | 1.32B | 1.12B | 785.53M | 611.97M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.29B | 1.62B | 1.76B | 1.73B | 1.51B | Total Assets |
| 12.60B | 11.97B | 10.97B | 10.71B | 9.25B | Total Debt |
| 3.64B | 3.37B | 3.21B | 3.11B | 2.44B | Net Debt |
| 2.38B | 1.76B | 1.50B | 1.41B | 984.62M | Total Liabilities |
| 5.07B | 4.70B | 4.26B | 4.11B | 3.24B | Stockholders Equity |
| 7.22B | 6.93B | 6.21B | 6.22B | 5.65B |
| Cash Flow | Free Cash Flow | |||
| -49.39M | 221.88M | 368.70M | 359.58M | 236.61M | Operating Cash Flow |
| 491.03M | 925.75M | 786.82M | 747.91M | 527.64M | Investing Cash Flow |
| -521.76M | -640.19M | -412.77M | -681.23M | -287.58M | Financing Cash Flow |
| -295.42M | -304.57M | -219.30M | 136.13M | 318.57M |
SSY Group Technical Analysis
SSY Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | HK$9.67B | 9.67 | 23.28% | 4.89% | 12.70% | 9.91% | |
75 Outperform | HK$5.65B | 6.20 | 11.61% | 7.44% | -18.09% | -15.08% | |
73 Outperform | HK$1.85B | 3.02 | 18.33% | 5.12% | -9.95% | 67.56% | |
72 Outperform | $8.62B | 8.15 | 14.96% | 5.87% | -10.67% | -19.27% | |
70 Outperform | HK$9.37B | 8.80 | 8.89% | 4.78% | 4.91% | -11.80% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
51 Neutral | $10.82B | ― | -4.93% | 2.69% | -0.11% | -290.77% |
SSY Group Corporate Events
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Timolol Maleate Eye Drops in unit dose packaging. This marks the company’s first approval of this kind in China and is part of its strategy to expand its ophthalmic product line. The new product is designed to effectively reduce intraocular pressure in various types of glaucoma, enhancing SSY Group’s position in the pharmaceutical market and potentially opening new sales channels by the end of the year.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two chemical drugs: Calcium Gluconate and Sodium Chloride Injection, and Potassium Chloride Granules. These approvals mark a significant step in the company’s product development, enhancing its portfolio in treating conditions such as acute hypocalcemia and hypokalemia, which could strengthen its market position and offer new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited announced a significant decline in its unaudited operating results for the first quarter of 2025, with a 36.9% decrease in turnover compared to the same period in 2024. The drop in sales volume of intravenous infusion solutions and ampoule injections contributed to a 50.6% decrease in gross profit and a 59.5% decrease in profit attributable to shareholders. This downturn in financial performance could impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its Low Calcium Peritoneal Dialysis Solution has passed the Consistency Evaluation of the Quality and Efficacy of Generic Drugs by the National Medical Products Administration of China. This development marks a significant advancement for the company, enhancing its product offerings in the treatment of renal failure and potentially strengthening its position in the pharmaceutical market.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of two drugs: Dronedarone Hydrochloride Tablets and Gabexate Mesylate for Injection. These approvals mark significant advancements in the company’s product offerings, with Dronedarone Hydrochloride targeting atrial fibrillation and Gabexate Mesylate addressing acute pancreatitis. This development enhances SSY Group’s position in the pharmaceutical market, potentially benefiting stakeholders by expanding the company’s portfolio and market reach.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited held its Annual General Meeting (AGM) in 2025, where all proposed resolutions were passed. Key decisions included the re-election of executive directors, the re-appointment of KPMG as the auditor, and the approval of a final dividend. The meeting also granted the board of directors mandates to issue and repurchase shares, reflecting strong shareholder support and potentially impacting the company’s future financial strategies.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its drug Riluzole has received approval from the National Medical Products Administration of China for market use as a bulk drug. This development is significant as Riluzole is used to extend the life of patients with amyotrophic lateral sclerosis (ALS) or delay the need for mechanical ventilation. The approval marks a crucial step in SSY Group’s product development, potentially enhancing its market position and offering new treatment options for ALS patients.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$5.20 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its product, Lornoxicam, has received approval from the National Medical Products Administration of China for registration as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position in the pharmaceutical industry by expanding its portfolio of pain management solutions.
SSY Group Limited has announced that its product, Allopurinol, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, particularly in the treatment of gout and high uric acid, potentially enhancing its position in the pharmaceutical market.
SSY Group Limited has received approvals from the National Medical Products Administration of China for the production and registration of new pharmaceutical products, including Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets and Ibuprofen Arginine Granules. These developments are expected to enhance the company’s product offerings in diabetes management and pain relief. Additionally, the company has obtained registration approvals for Acipimox and Diprophylline as bulk drugs, which will support their market presence in treating hyperlipidemia and respiratory conditions.
SSY Group Limited has announced its upcoming annual general meeting scheduled for May 16, 2025, in Hong Kong. Key agenda items include the adoption of the company’s financial statements for the year ending December 31, 2024, re-election of directors, and the re-appointment of KPMG as auditors. Additionally, a final dividend of HK$0.095 per share is proposed, and resolutions concerning the issuance of additional shares will be considered. These decisions are crucial for maintaining the company’s governance structure and financial strategies, potentially impacting shareholder value and market positioning.
SSY Group Limited announced that its Felodipine drug has received approval from the National Medical Products Administration of China for market preparations, marking a significant step in its product development. This approval is expected to enhance the company’s market position in the pharmaceutical industry, particularly in China, and could have positive implications for shareholders and investors.
SSY Group Limited has announced the approval of its SYN045 tablets for Phase I clinical trials by the National Medical Products Administration of China. The approval includes three different specifications, which will enhance the clinical application and dosing precision of the drug. SYN045, a PGI2 receptor agonist, has shown promising results in preclinical studies with good targeting selectivity and safety, marking a significant step forward in the company’s drug development efforts.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of two new injectable drugs: Nicardipine Hydrochloride Injection and Sodium Bicarbonate Injection. These approvals mark significant progress in the company’s product development, enhancing its portfolio in emergency and metabolic treatment solutions, potentially strengthening its market position and offering new opportunities for growth.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Arbidol Hydrochloride Tablets, a drug used to treat various viral infections including influenza and coronavirus-related illnesses. This approval marks a significant step in the company’s product development, potentially enhancing its market position and offering new treatment options for respiratory infections.
SSY Group Limited faced a challenging business environment in 2024, marked by sluggish economic recovery and intensified trade protectionism. Despite these challenges, the company maintained stable development by focusing on innovation and optimizing its product mix. The company reported a revenue of approximately HK$5,773 million, a decrease of 10.7% from the previous year, and a net profit of HK$1,061 million, down by 19.5%. The company declared a final dividend of HK$0.095 per share, with a total dividend for the year increasing by 2.9%.
SSY Group Limited has announced a final ordinary cash dividend of HKD 0.095 per share for the financial year ending December 31, 2024. The dividend will be paid on June 3, 2025, following shareholder approval on May 16, 2025. This announcement reflects the company’s financial performance and commitment to returning value to shareholders, potentially enhancing its market position and investor confidence.
SSY Group Limited has received approval from China’s National Medical Products Administration for the production and registration of Voriconazole for Oral Suspension, a drug used to treat and prevent serious fungal infections. This development marks a significant step in SSY Group’s product offerings, potentially enhancing its market position and providing new treatment options for patients, particularly those undergoing high-risk medical procedures.
SSY Group Limited has announced that its product, Nimodipine, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing new opportunities for growth in the pharmaceutical sector.
SSY Group Limited, a company incorporated in the Cayman Islands, has announced that its Board of Directors will meet on March 28, 2025, to approve the annual results for the year ending December 31, 2024, and to consider recommending a final dividend. This meeting is significant as it will determine the company’s financial performance and potential returns for shareholders, impacting its market positioning and stakeholder interests.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Epinephrine Hydrochloride Injection, a critical drug for cardiopulmonary resuscitation and treatment of severe dyspnea and anaphylaxis. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing stakeholders with an updated view of its business advancements.